BRUSSELS, April 25 Belgian drugmaker UCB
had a difficult first quarter as cold spring weather in
Europe meant fewer hay fever sufferers were buying its allergy
medicines, it said on Thursday.
Its revenues for the quarter slipped 9 percent to 799
million euros ($1.04 billion) impacted by slower sales of its
allergy drugs Xyzal and Zyrtec, and as generic competition
continues to eat into its former blockbuster Keppra, an epilepsy
It said Keppra sales fell 23 percent, but reiterated its
full-year guidance for revenue of about 3.4 billion euros as its
new range of drugs continue to pick up the slack.
($1 = 0.7695 euros)
(Reporting By Ben Deighton, Editing By Ethan Bilby)